Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Gains from Investment Securities (2020 - 2025)

HCW Biologics (HCWB) has disclosed Gains from Investment Securities for 5 consecutive years, with $14484.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Investment Securities fell 45.02% year-over-year to $14484.0, compared with a TTM value of $26342.0 through Dec 2023, down 98.59%, and an annual FY2024 reading of $14484.0, down 45.02% over the prior year.
  • Gains from Investment Securities was $14484.0 for Q4 2024 at HCW Biologics, down from $26342.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.9 million in Q4 2022 and bottomed at $14484.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $884214.0, with a median of $742047.0 recorded in 2020.
  • The sharpest move saw Gains from Investment Securities soared 138.63% in 2021, then plummeted 98.59% in 2023.
  • Year by year, Gains from Investment Securities stood at $742047.0 in 2020, then skyrocketed by 138.63% to $1.8 million in 2021, then increased by 5.46% to $1.9 million in 2022, then tumbled by 98.59% to $26342.0 in 2023, then tumbled by 45.02% to $14484.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for HCWB at $14484.0 in Q4 2024, $26342.0 in Q4 2023, and $1.9 million in Q4 2022.